NCT03778047View on ClinicalTrials.gov

A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 7, 2018

Primary Completion Date

October 24, 2018

Study Completion Date

August 28, 2019

Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
DRUG

Enzalutamide

oral

DRUG

HC1119

oral

Trial Locations (1)

Unknown

Medical Ethics Committee of Hunan Cancer Hospital, Changsha

Sponsors
All Listed Sponsors
lead

Hinova Pharmaceuticals Inc.

INDUSTRY

NCT03778047 - A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch | Biotech Hunter | Biotech Hunter